An interventional study of Time-restricted eating combined with resistance exercise (TRE+Ex) and Habitual eating pattern combined with resistance exercise (HE+Ex) in Osteopenia, sponsored by University of Alabama at Birmingham. Not yet recruiting at 1 site in United States. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Among 217 studies in Bone Diseases, Metabolic with a site in United States — 16 open to participants now, 21 under way, 1 of them phase 3. Bone Diseases, Metabolic · United States.
Among the 217 studies in Bone Diseases, Metabolic with a site in United States, this one is the 128th largest by planned enrollment of the 171 interventional ones that give a count, is one of 4 that started in 2026, is one of 57 with no phase, reaches primary completion later than 9 of the 20 other live ones, and was the 217th registered.
661 studies on the registry are indexed under Bone Diseases, Metabolic; 93 are open to participants now.
Browse Bone Diseases, Metabolic studies →16 of the 217 studies in Bone Diseases, Metabolic with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Tufts Medical Center · Sites in United States
Ages 50+
AO Innovation Translation Center · Sites in United States, Australia, Brazil and 11 more countries
Ages 18+
San Diego State University · Sites in United States
Women only
Texas A&M University · Sites in United States
Ages 18–45 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 63 Bone Diseases, Metabolic studies recruiting now, 27 (43%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 37 · Phase 3 39 · Phase 4 28
First in 1992; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 66 across the 171 interventional studies, 61 across the 45 observational. Of the 180 that completed or were terminated, 82 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 217 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,421 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 5 studies filed under Bone Diseases, Metabolic — fewer than ten, so there is no comparison to draw.
5 of the studies in Bone Diseases, Metabolic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04954664University of Alabama at BirminghamRidge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor | 2026-12 |
| NCT03374215National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks | 2026-12-31 |
| NCT05704036Johns Hopkins UniversityEstrogen Supplementation and Bone Health in Women With CF | 2027-01 |
| NCT05058976Susan L. GreenspanRomosozumab Use to Build Skeletal Integrity | 2027-03-31 |
| NCT07763509Cornell UniversityCalcium-Rich Food Versus Calcium Carbonate for Bone Health | 2027-06-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 217 studies in Bone Diseases, Metabolic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn whether combining time-restricted eating with supervised resistance exercise can improve bone health in adults with osteopenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the TRE+Ex group will be asked to fast for a target of 16 hours per day, consuming food ad libitum within an 8-hour eating window beginning between 6:30 and 9:30 AM, 6 days per week for 12 weeks. They will also complete supervised progressive resistance exercise training 3 days per week.
Behavioral: Time-restricted eating combined with resistance exercise (TRE+Ex)
Participants in the HE+Ex group will be instructed to maintain their habitual eating patterns and complete supervised progressive resistance exercise training 3 days per week.
Behavioral: Habitual eating pattern combined with resistance exercise (HE+Ex)
Participants in the TRE+Ex group will be asked to fast for a target of 16 hours per day, consuming food ad libitum within an 8-hour eating window beginning between 6:30 and 9:30 AM, 6 days per week for 12 weeks. They will also complete supervised progressive resistance exercise training 3 days per week.
Participants in the HE+Ex group will be instructed to maintain their habitual eating patterns and complete supervised progressive resistance exercise training 3 days per week.
Bone mineral density
measured by dual-energy X-ray absorptiometry
Time frame: Baseline and 12 weeks
Bone mineral content
measured by dual-energy X-ray absorptiometry
Time frame: Baseline and 12 weeks
Plan to share: Undecided — IPD may not be shared due to concerns regarding participant privacy and the sensitive nature of the health-related data collected.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 13 months is below that.
Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →